Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis

Journal of Dermatology

Volumn 41, Issue 3, 2014, Pages 221-229

  Kataoka, Yoko ^a  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

atopic dermatitis; biomarker; outcome; proactive therapy; thymus and activation regulated chemokine

Indexed keywords

ANTIINFLAMMATORY AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; THYMUS AND ACTIVATION REGULATED CHEMOKINE; BIOLOGICAL MARKER; CCL17 PROTEIN, HUMAN;

ATOPIC DERMATITIS; DERMATOLOGIST; DISEASE ACTIVITY; DISEASE SEVERITY; EARLY INTERVENTION; ECZEMA; FOOD ALLERGY; HUMAN; INFANT DISEASE; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT COMPLIANCE; PROGNOSIS; PROTEIN EXPRESSION; REMISSION; REVIEW; UPREGULATION; BLOOD; DERMATITIS, ATOPIC;

BIOLOGICAL MARKERS; CHEMOKINE CCL17; DERMATITIS, ATOPIC; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 84896344225     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12440     Document Type: Review

References (39)

1. Imai T, Yoshida T, Baba M, Nishimura M, Kakizaki M, Yoshie O,. Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector. J Biol Chem 1996; 271: 1514-1521.
2. Bieber T,. Atopic dermatitis. Ann Dermatol 2010; 22: 125-137.
3. Kakinuma T, Nakamura K, Wakugawa M, et al,. Thymus and activation-regulated chemokine in atopic dermatitis: serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol 2001; 107: 535-541.
4. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG,. A Th2 chemokine, TARC, produced by keratinocytes may recruit CLA+CCR4 + lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 2000; 115: 640-646.
5. Hijnen D, De Bruin-Weller M, Oosting B, et al,. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113: 334-340.
6. Hon KL, Leung TF, Ma KC, Li AM, Wong Y, Fok TF,. Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children. Clin Exp Dermatol 2004; 29: 293-296.
7. Kagami S, Kakinuma T, Saeki H, et al,. Significant elevation of serum levels of eotaxin-3/CCL26, but not of eotaxin-2/CCL24, in patients with atopic dermatitis: serum eotaxin-3/CCL26 levels reflect the disease activity of atopic dermatitis. Clin Exp Immunol 2003; 134: 309-313.
8. Kakinuma T, Nakamura K, Wakugawa M, et al,. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin Exp Immunol 2002; 127: 270-273.
9. Leung TF, Ma KC, Hon KL, et al,. Serum concentration of macrophage-derived chemokine may be a useful inflammatory marker for assessing severity of atopic dermatitis in infants and young children. Pediatr Allergy Immunol 2003; 14: 296-301.
10. Ohta S, Taniguchi K, Arima K, et al,. Establishment of novel biomarkers for Personalized medication for atopic dermatitis. Rinsho Byori 2013; 61: 247-255.
11. Tamaki K, Saeki H, Kadono T, Sato S,. Serum TARC/CCL17 levels as a disease marker of atopic dermatitis. Jap J Dermatol 2006; 116: 27-39.
12. Fujisawa T, Nagao M, Hiraguchi Y, et al,. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis. Pediatr Allergy Immunol 2009; 20: 633-641.
13. Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A,. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis. Allergy 2005; 60: 685-688.
14. Mukai H, Noguchi T, Kamimura K, Nishioka K, Nishiyama S,. Significance of elevated serum LDH (lactate dehydrogenase) activity in atopic dermatitis. J Dermatol 1990; 17: 477-481.
15. Wüthrich B, Benz A, Skvaril F,. IgE and IgG4 levels in children with atopic dermatitis. Dermatologica 1983; 166: 229-235.
16. Gebhardt M, Wenzel HC, Hipler UC, Herrmann D, Wollina U,. Monitoring of serologic immune parameters in inflammatory skin diseases. Allergy 1997; 52: 1087-1094.
17. Kägi MK, Joller-Jemelka H, Wüthrich B,. Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitis. Dermatology 1992; 185: 88-92.
18. Simon D, Braathen LR, Simon HU,. Eosinophils and atopic dermatitis. Allergy 2004; 59: 561-570.
19. Maeda N, Kataoka Y, Nishino H,. The clinical significance of serum TARC as a biomarker for severe adult atopic dermatitis. J Environ Dermatol Cutan Allergol 2011; 5: 27-35.
20. Wollenberg A, Ehmann LM,. Long term treatment concepts and proactive therapy for atopic eczema. Ann Dermatol 2012; 24: 253-260.
21. Schmitt J, von Kobyletzki L, Svensson A, Apfelbacher C,. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2011; 164: 415-428.
22. Bangert C, Strober BE, Cork M, et al,. Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial. Dermatology 2011; 222: 36-48.
23. Sekiya T, Miyamasu M, Imanishi M, et al,. Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J Immunol 2000; 165: 2205-2213.
24. Furukawa H, Nakamura K, Zheng X, et al,. Enhanced TARC production by dust-mite allergens and its modulation by immunosuppressive drugs in PBMCs from patients with atopic dermatitis. J Dermatol Sci 2004; 35: 35-42.
25. Soumelis V, Reche PA, Kanzler H, et al,. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3: 673-680.
26. Vestergaard C, Deleuran M, Gesser B, Larsen CG,. Thymus- and activation-regulated chemokine (TARC/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice. Exp Dermatol 2004; 13: 265-271.
27. Brandt EB, Sivaprasad U,. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011; 2: 110-134.
28. Xiao T, Fujita H, Saeki H, et al,. Thymus and activation-regulated chemokine (TARC/CCL17) produced by mouse epidermal Langerhans cells is upregulated by TNF-alpha and IL-4 and downregulated by IFN-gamma. Cytokine 2003; 23: 126-132.
29. Lack G,. Epidemiologic risks for food allergy. J Allergy Clin Immunol 2008; 121: 1331-1336.
30. Illi S, von Mutius E, Lau S, et al,. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol 2004; 113: 925-931.
31. Hill DJ, Hosking CS, de Benedictis FM, Oranje AP, Diepgen TL, Bauchau V,; EPAAC Study Group. Confirmation of the association between high levels of immunoglobulin E food sensitization and eczema in infancy: an international study. Clin Exp Allergy 2008; 38: 161-168.
32. Miyahara H, Okazaki N, Nagakura T, Korematsu S, Izumi T,. Elevated umbilical cord serum TARC/CCL17 levels predict the development of atopic dermatitis in infancy. Clin Exp Allergy 2011; 41: 186-191.
33. Saeki H, Tamaki K,. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. J Dermatol Sci 2006; 43: 75-84.
34. Kakinuma T, Sugaya M, Nakamura K, et al,. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003; 48: 23-30.
35. Quaglino P, Caproni M, Antiga E, et al,. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology. Dermatology 2007; 214: 296-304.
36. Ono S, Otsuka A, Miyachi Y, Kabashima K,. Subcorneal pustular dermatosis exhibiting a high serum TARC/CCL17 level. Case Rep Dermatol 2013; 5: 38-42.
37. Roumier AS, Grardel N, Laï JL, et al,. Hypereosinophilia with abnormal T cells, trisomy 7 and elevated TARC serum level. Haematologica 2003; 88: 104-107.
38. Sauer M, Plütschow A, Jachimowicz RD, et al,. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol 2013; 88: 113-115.
39. Dallos T, Heiland GR, Strehl J, et al,. CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum 2010; 62: 3496-3503.